

# Gavin P Reynolds

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1929325/publications.pdf>

Version: 2024-02-01

352  
papers

20,247  
citations

7551

77  
h-index

13338

130  
g-index

359  
all docs

359  
docs citations

359  
times ranked

13073  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains. Journal of Neurochemistry, 1989, 52, 515-520.	2.1	1,324
2	Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. Journal of Neural Transmission, 1988, 74, 199-205.	1.4	685
3	A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophrenia Research, 2002, 55, 1-10.	1.1	416
4	Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature, 1983, 305, 527-529.	13.7	400
5	Human brain dopamine receptors in children and aging adults. Synapse, 1987, 1, 399-404.	0.6	396
6	Association of antipsychotic drug-induced weight gain with a 5-HT <sub>2C</sub> receptor gene polymorphism. Lancet, The, 2002, 359, 2086-2087.	6.3	392
7	Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia. Journal of Neurochemistry, 1989, 52, 1781-1786.	2.1	382
8	Neurochemical characteristics of early and late onset types of Alzheimer's disease.. BMJ: British Medical Journal, 1984, 288, 961-964.	2.4	375
9	Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biological Psychiatry, 2002, 52, 708-715.	0.7	348
10	Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science, 1984, 225, 728-731.	6.0	345
11	Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophrenia Research, 1997, 24, 349-355.	1.1	343
12	Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms. , 2010, 125, 169-179.		327
13	Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology, 1987, 1, 5-15.	2.8	289
14	Deprenyl is metabolized to methamphetamine and amphetamine in man.. British Journal of Clinical Pharmacology, 1978, 6, 542-544.	1.1	270
15	Loss of pigmented dopamine-β-hydroxylase positive cells from locus coeruleus in senile dementia of alzheimer's type. Neuroscience Letters, 1983, 39, 95-100.	1.0	270
16			

#	ARTICLE	IF	CITATIONS
19	BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. <i>Journal of Psychopharmacology</i> , 2016, 30, 717-748.	2.0	200
20	Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. <i>British Journal of Psychiatry</i> , 2004, 184, 58-62.	1.7	199
21	Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. <i>Biological Psychiatry</i> , 1990, 27, 1038-1044.	0.7	198
22	Polymorphism of the Promoter Region of the Serotonin 5-HT <sub>2C</sub> Receptor Gene and Clozapine-Induced Weight Gain. <i>American Journal of Psychiatry</i> , 2003, 160, 677-679.	4.0	195
23	3H-spiperone binding sites in post-mortem brains from schizophrenic patients: Relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. <i>Journal of Neural Transmission</i> , 1989, 75, 1-10.	1.4	194
24	Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. <i>Journal of Psychopharmacology</i> , 2007, 21, 198-205.	2.0	193
25	5-HT <sub>4</sub> receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. <i>British Journal of Pharmacology</i> , 1995, 114, 993-998.	2.7	179
26	ASYMMETRICAL LOSS OF GLUTAMATE RECEPTOR SUBTYPE IN LEFT HIPPOCAMPUS IN SCHIZOPHRENIA. <i>Lancet, The</i> , 1988, 331, 583-584.	6.3	166
27	Beyond the Dopamine Hypothesis. <i>British Journal of Psychiatry</i> , 1989, 155, 305-316.	1.7	156
28	GABAergic neuronal subtypes in the human frontal cortex – development and deficits in schizophrenia. <i>Journal of Chemical Neuroanatomy</i> , 2001, 22, 95-100.	1.0	147
29	Monoclonal antibodies raised against a subsequence of senile plaque core protein react with plaque cores, plaque periphery and cerebrovascular amyloid in Alzheimer's disease. <i>Neuroscience Letters</i> , 1986, 68, 252-256.	1.0	146
30	Region-specific loss of glutamate innervation in Alzheimer's disease. <i>Neuroscience Letters</i> , 1987, 73, 77-80.	1.0	146
31	NEURONAL DEGENERATION IN LOCUS CERULEUS AND CORTICAL CORRELATES OF ALZHEIMER DISEASE. <i>Alzheimer Disease and Associated Disorders</i> , 1987, 1, 256-262.	0.6	145
32	Developments in the drug treatment of schizophrenia. <i>Trends in Pharmacological Sciences</i> , 1992, 13, 116-121.	4.0	145
33	Calcium binding protein markers of GABA deficits in schizophrenia – post mortem studies and animal models. <i>Neurotoxicity Research</i> , 2004, 6, 57-61.	1.3	145
34	Reduced binding of [3H]ketanserin to cortical 5-HT <sub>2</sub> receptors in senile dementia of the Alzheimer type. <i>Neuroscience Letters</i> , 1984, 44, 47-51.	1.0	138
35	The 5-HT <sub>2C</sub> receptor and antipsychotic-induced weight gain – mechanisms and genetics. <i>Journal of Psychopharmacology</i> , 2006, 20, 15-18.	2.0	137
36	Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity. <i>Brain Research Bulletin</i> , 2001, 55, 579-584.	1.4	136

#	ARTICLE	IF	CITATIONS
37	Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. <i>Neuroscience Letters</i> , 1992, 144, 199-201.	1.0	135
38	Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats. <i>Journal of Neural Transmission</i> , 2007, 114, 893-898.	1.4	134
39	Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. <i>Journal of Neural Transmission</i> , 1978, 43, 271-277.	1.4	133
40	Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. <i>Journal of Psychiatric Research</i> , 1995, 29, 227-232.	1.5	132
41	Pre-frontal structural and functional deficits associated with individual differences in schizotypal personality. <i>Schizophrenia Research</i> , 1992, 7, 237-247.	1.1	131
42	The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. <i>Behavioural Brain Research</i> , 2006, 169, 263-273.	1.2	128
43	The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 1021-1028.	2.5	125
44	Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. <i>European Neuropsychopharmacology</i> , 2005, 15, 143-151.	0.3	124
45	Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and $\hat{1}^3$ -glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. <i>Journal of the Neurological Sciences</i> , 1985, 67, 161-171.	0.3	122
46	The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. <i>Neuroscience Letters</i> , 2004, 372, 173-177.	1.0	122
47	DOES PHENYLETHYLAMINE CAUSE SCHIZOPHRENIA?. <i>Lancet, The</i> , 1976, 307, 70-71.	6.3	120
48	[3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. <i>European Journal of Pharmacology</i> , 1985, 114, 235-237.	1.7	118
49	Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. <i>Neuroscience</i> , 1988, 25, 419-438.	1.1	117
50	Dopamine deficits in the brain. <i>NeuroReport</i> , 1996, 7, 910-912.	0.6	117
51	Neuronal calcium-binding proteins and schizophrenia. <i>Schizophrenia Research</i> , 2002, 57, 27-34.	1.1	114
52	Hippocampal tin, aluminum and zinc in Alzheimer's disease. <i>BioMetals</i> , 1993, 6, 149-54.	1.8	112
53	Brain Quinolinic Acid in Huntington's Disease. <i>Journal of Neurochemistry</i> , 1988, 50, 1959-1968.	2.1	105
54	Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1987, 50, 775-778.	0.9	104

#	ARTICLE	IF	CITATIONS
55	A disorder of cortical GABAergic innervation in Alzheimer's disease. <i>Neuroscience Letters</i> , 1987, 73, 192-196.	1.0	104
56	Structural and Functional Characteristics of the Corpus Callosum in Schizophrenics, Psychiatric Controls, and Normal Controls. <i>Archives of General Psychiatry</i> , 1990, 47, 1060.	13.8	104
57	The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. <i>Journal of Psychopharmacology</i> , 2003, 17, 57-66.	2.0	103
58	Receptor Mechanisms in the treatment of Schizophrenia. <i>Journal of Psychopharmacology</i> , 2004, 18, 340-345.	2.0	102
59	Effect of 5-HT <sub>1A</sub> Receptor Gene Polymorphism on Negative and Depressive Symptom Response to Antipsychotic Treatment of Drug-Naive Psychotic Patients. <i>American Journal of Psychiatry</i> , 2006, 163, 1826-1829.	4.0	100
60	The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. <i>Journal of Neurochemistry</i> , 2002, 81, 46-59.	2.1	98
61	Monoamine neurotransmitters and their metabolites in brain regions in alzheimer's disease: A postmortem study. <i>Cellular and Molecular Neurobiology</i> , 1992, 12, 581-587.	1.7	97
62	Deficient production of tyramine and octopamine in cases of depression. <i>Nature</i> , 1979, 278, 357-358.	13.7	96
63	Dopamine D2 receptor density remains constant in treated Parkinson's disease. <i>Annals of Neurology</i> , 1986, 19, 487-492.	2.8	96
64	An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures. <i>Psychiatry Research - Neuroimaging</i> , 1992, 45, 123-137.	0.9	93
65	Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. <i>International Clinical Psychopharmacology</i> , 1993, 8, 151-154.	0.9	92
66	Neuroanatomical Correlates of Skin Conductance Orienting in Normal Humans: A Magnetic Resonance Imaging Study. <i>Psychophysiology</i> , 1991, 28, 548-558.	1.2	89
67	Age and Histopathologic Heterogeneity in Alzheimer's Disease. <i>Archives of General Psychiatry</i> , 1987, 44, 412.	13.8	87
68	Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease. <i>Neuroscience Letters</i> , 1998, 241, 53-56.	1.0	87
69	Are Striatal Dopamine D <sub>4</sub> Receptors Increased in Schizophrenia?. <i>Journal of Neurochemistry</i> , 1994, 63, 1576-1577.	2.1	87
70	Clozapine-induced hypersalivation and the alpha2 adrenoceptor. <i>British Journal of Psychiatry</i> , 1995, 167, 412-412.	1.7	86
71	Brain Neurotransmitter Deficits in Mice Transgenic for the Huntington's Disease Mutation. <i>Journal of Neurochemistry</i> , 2001, 72, 1773-1776.	2.1	84
72	Acute and chronic tryptophan depletion differentially regulate central 5-HT <sub>1A</sub> and 5-HT <sub>2A</sub> receptor binding in the rat. <i>Psychopharmacology</i> , 2007, 190, 497-506.	1.5	84

#	ARTICLE	IF	CITATIONS
73	Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations. <i>JAMA - Journal of the American Medical Association</i> , 1985, 254, 3067-3069.	3.8	84
74	Increased Concentrations of the Neurotoxin 3- $\beta$ -Hydroxykynurenine in the Frontal Cortex of HIV-1-Positive Patients. <i>Journal of Neurochemistry</i> , 1995, 64, 932-935.	2.1	81
75	Influence of 5-HT <sub>2C</sub> receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. <i>British Journal of Psychiatry</i> , 2008, 192, 424-428.	1.7	81
76	Hippocampal neurochemistry is involved in the behavioural effects of neonatal maternal separation and their reversal by post-weaning environmental enrichment: A magnetic resonance study. <i>Behavioural Brain Research</i> , 2011, 217, 122-127.	1.2	81
77	Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons. <i>Journal of Neural Transmission</i> , 2002, 109, 881-889.	1.4	80
78	Region specific changes in forebrain 5-hydroxytryptamine <sub>1a</sub> and 5-hydroxytryptamine <sub>2a</sub> receptors in isolation-reared rats: an in vitro autoradiography study. <i>Neuroscience</i> , 2004, 123, 725-732.	1.1	80
79	Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain. <i>Neuroscience Letters</i> , 1987, 78, 233-238.	1.0	78
80	Dopamine depletion of the nucleus accumbens reverses isolation-induced deficits in prepulse inhibition in rats. <i>Neuroscience</i> , 2003, 119, 233-240.	1.1	77
81	Olanzapine-induced weight gain in the rat: role of 5-HT <sub>2C</sub> and histamine H <sub>1</sub> receptors. <i>Psychopharmacology</i> , 2009, 207, 119-125.	1.5	76
82	Absence of detectable striatal dopamine D <sub>4</sub> receptors in drug-treated schizophrenia. <i>European Journal of Pharmacology</i> , 1995, 281, R5-R6.	1.7	73
83	Chronic clozapine treatment of rats down-regulates cortical 5-HT <sub>2</sub> receptors. <i>European Journal of Pharmacology</i> , 1983, 89, 325-326.	1.7	69
84	Serotonin concentrations and turnover in brains of depressed suicides. <i>Brain Research</i> , 1989, 502, 332-340.	1.1	68
85	Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia. <i>Neuroscience Letters</i> , 1995, 187, 9-12.	1.0	68
86	Association of a polymorphism in the promoter region of the serotonin 5-HT <sub>2C</sub> receptor gene with tardive dyskinesia in patients with schizophrenia. <i>Molecular Psychiatry</i> , 2002, 7, 670-671.	4.1	68
87	Schizophrenia-related endophenotypes in heterozygous neuregulin <sup>1</sup> knockout <sup>TM</sup> mice. <i>European Journal of Neuroscience</i> , 2010, 31, 349-358.	1.2	68
88	Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease. <i>Neuroscience Letters</i> , 1986, 67, 198-202.	1.0	64
89	Arachidonic Acid: A Common Link in the Biology of Schizophrenia?. <i>Archives of General Psychiatry</i> , 1994, 51, 665.	13.8	61
90	Characterization of [ <sup>3</sup> H]GR 113808 binding to 5-HT <sub>4</sub> receptors in brain tissues from patients with neurodegenerative disorders. <i>Behavioural Brain Research</i> , 1995, 73, 249-252.	1.2	60

#	ARTICLE	IF	CITATIONS
91	Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. <i>Journal of Psychopharmacology</i> , 2012, 26, 349-359.	2.0	60
92	Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. <i>European Journal of Pharmacology</i> , 1992, 221, 397-398.	1.7	59
93	The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. <i>Journal of Psychiatric Research</i> , 2002, 36, 317-324.	1.5	58
94	N-acetylaspartate and N-Acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study. <i>Biological Psychiatry</i> , 2003, 53, 1138-1141.	0.7	57
95	Neonatal lipopolysaccharide induces pathological changes in parvalbumin immunoreactivity in the hippocampus of the rat. <i>Behavioural Brain Research</i> , 2009, 205, 355-359.	1.2	57
96	Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients. <i>Psychiatry Research</i> , 1983, 8, 243-250.	1.7	55
97	Recommended minimum data to be collected in research studies on Alzheimer's disease. The MRC (UK) Alzheimer's Disease Workshop Steering Committee.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1989, 52, 693-700.	0.9	55
98	Amino acid neurotransmitter deficits in adult Down's syndrome brain tissue. <i>Neuroscience Letters</i> , 1988, 94, 224-227.	1.0	54
99	INCREASED BRAIN 3-HYDROXYKYNURENINE IN HUNTINGTON'S DISEASE. <i>Lancet, The</i> , 1989, 334, 979-980.	6.3	54
100	Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata. <i>Neuroscience Letters</i> , 1989, 100, 335-339.	1.0	53
101	Learning and Memory Alterations Are Associated with Hippocampal N-acetylaspartate in a Rat Model of Depression as Measured by 1H-MRS. <i>PLoS ONE</i> , 2011, 6, e28686.	1.1	53
102	Neuropeptides in Alzheimer's disease: a postmortem study. <i>Regulatory Peptides</i> , 1989, 25, 123-130.	1.9	52
103	Determination of 3-hydroxykynurenine in human brain and plasma by high-performance liquid chromatography with electrochemical detection. <i>Biomedical Applications</i> , 1991, 565, 436-440.	1.7	52
104	The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. <i>Journal of Psychopharmacology</i> , 2002, 16, 35-37.	2.0	51
105	Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. <i>Schizophrenia Research</i> , 2005, 75, 303-308.	1.1	51
106	Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 645-649.	1.0	51
107	Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. <i>Journal of Affective Disorders</i> , 2010, 123, 308-311.	2.0	50
108	Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. <i>Pharmacogenomics</i> , 2011, 12, 1127-1136.	0.6	50

#	ARTICLE	IF	CITATIONS
109	Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat. <i>Neuroscience Letters</i> , 2010, 471, 144-147.	1.0	49
110	Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review. <i>Clinical Psychopharmacology and Neuroscience</i> , 2012, 10, 71-77.	0.9	49
111	Increased density of glutamate/N-methyl-d-aspartate receptors in putamen from schizophrenic patients. <i>Neuroscience Letters</i> , 1998, 241, 143-146.	1.0	48
112	5-HT <sub>2C</sub> receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity. <i>Brain Research</i> , 2007, 1149, 14-17.	1.1	48
113	Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment. <i>Journal of Psychopharmacology</i> , 2017, 31, 1430-1436.	2.0	47
114	Neurotensin in the adrenal medulla. <i>Neuroscience Letters</i> , 1983, 35, 155-160.	1.0	46
115	Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. <i>Schizophrenia Research</i> , 2005, 73, 147-152.	1.1	46
116	Interaction between polymorphisms of the dopamine D <sub>3</sub> receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. <i>Psychiatric Genetics</i> , 2003, 13, 187-192.	0.6	45
117	Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat. <i>Behavioural Brain Research</i> , 2008, 194, 230-235.	1.2	45
118	<i> DAT1 </i> methylation is associated with methylphenidate response on oppositional and hyperactive-impulsive symptoms in children and adolescents with ADHD. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 291-299.	1.3	44
119	Electrochemical detection of human brain transmitter amino acids by high-performance liquid chromatography of stable O-phthalaldehyde-sulphite derivatives. <i>Journal of Neural Transmission</i> , 1991, 86, 151-157.	1.4	43
120	Imidazoline binding sites in Huntington's and Parkinson's disease putamen. <i>European Journal of Pharmacology</i> , 1996, 301, R19-R21.	1.7	43
121	Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response. <i>Pharmacogenomics</i> , 2013, 14, 277-288.	0.6	43
122	The Importance of Dopamine D <sub>4</sub> Receptors in the Action and Development of Antipsychotic Agents. <i>Drugs</i> , 1996, 51, 7-11.	4.9	42
123	Differential regional N-acetylaspartate deficits in postmortem brain in schizophrenia, bipolar disorder and major depressive disorder. <i>Journal of Psychiatric Research</i> , 2011, 45, 54-59.	1.5	42
124	Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 654-672.	1.1	42
125	Deficits of neuronal glutamatergic markers in the caudate nucleus in schizophrenia. , 2007, , 281-285.		42
126	DOPAMINE RECEPTOR ASYMMETRY IN SCHIZOPHRENIA. <i>Lancet, The</i> , 1987, 329, 979.	6.3	41



#	ARTICLE	IF	CITATIONS
127	Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat. <i>Behavioural Brain Research</i> , 2010, 208, 132-136.	1.2	41
128	TETRAHYDROBIOPTERIN METABOLISM IN DEPRESSION. <i>Lancet, The</i> , 1984, 324, 163.	6.3	40
129	The impact of pharmacogenetics on the development and use of antipsychotic drugs. <i>Drug Discovery Today</i> , 2007, 12, 953-959.	3.2	39
130	Increased density of glutamate/N-methyl-d-aspartate receptors in superior temporal cortex in schizophrenia. <i>Neuroscience Letters</i> , 2001, 304, 9-12.	1.0	38
131	Effects of tranlycypromine stereoisomers on monamine oxidation in man.. <i>British Journal of Clinical Pharmacology</i> , 1980, 9, 521-523.	1.1	37
132	DOPAMINE RECEPTORS AND SCHIZOPHRENIA: DRUG EFFECT OR ILLNESS. <i>Lancet, The</i> , 1980, 316, 1251.	6.3	36
133	The neuronal pathology of schizophrenia: molecules and mechanisms. <i>Biochemical Society Transactions</i> , 2007, 35, 433-436.	1.6	36
134	SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 15-21.	1.2	36
135	Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. , 2006, , 39-43.		36
136	Phospholipid fatty acids and neurotoxicity in human neuroblastoma SH-SY5Y cells. <i>Neuroscience Letters</i> , 2001, 309, 193-196.	1.0	35
137	Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. <i>European Journal of Pharmacology</i> , 2004, 505, 253-254.	1.7	35
138	Effects of excitotoxic lesions of the rat prefrontal cortex on CREB regulation and presynaptic markers of dopamine and amino acid function in the nucleus accumbens. <i>European Journal of Neuroscience</i> , 1999, 11, 1265-1274.	1.2	34
139	Effect of acute tryptophan depletion on noradrenaline and dopamine in the rat brain. <i>Journal of Psychopharmacology</i> , 2009, 23, 51-55.	2.0	34
140	<i>GRIN2B</i> promoter methylation deficits in early-onset schizophrenia and its association with cognitive function. <i>Epigenomics</i> , 2019, 11, 401-410.	1.0	34
141	A selective reduction in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia patients. <i>Chinese Medical Journal</i> , 2002, 115, 819-23.	0.9	34
142	Deficits of [3H]d-aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia. <i>Neuroscience Letters</i> , 1997, 232, 13-16.	1.0	33
143	Selective increases in the cytokine, TNF $\alpha$ , in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs. <i>Journal of Psychopharmacology</i> , 2006, 20, 636-642.	2.0	33
144	Tryptophan depletion impairs object-recognition memory in the rat: Reversal by risperidone. <i>Behavioural Brain Research</i> , 2010, 208, 479-483.	1.2	33

#	ARTICLE	IF	CITATIONS
145	Receptor mechanisms of antipsychotic drug action in bipolar disorder – focus on asenapine. <i>Therapeutic Advances in Psychopharmacology</i> , 2011, 1, 197-204.	1.2	33
146	Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics. <i>Pharmacogenomics</i> , 2014, 15, 477-485.	0.6	33
147	Dementia in Huntington's disease is associated with neurochemical deficits in the caudate nucleus, not the cerebral cortex. <i>Neuroscience Letters</i> , 1990, 113, 95-100.	1.0	32
148	Parvalbumin promoter hypermethylation in postmortem brain in schizophrenia. <i>Epigenomics</i> , 2018, 10, 519-524.	1.0	32
149	Dopamine receptors and schizophrenia: the neuroleptic drug problem. <i>Neuropharmacology</i> , 1981, 20, 1319-20.	2.0	32
150	[3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia. <i>Journal of Neural Transmission</i> , 1989, 77, 227-230.	1.4	31
151	What is an atypical antipsychotic?. <i>Journal of Psychopharmacology</i> , 1997, 11, 195-199.	2.0	31
152	Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain. <i>Pharmacogenomics</i> , 2011, 12, 727-734.	0.6	31
153	Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. <i>Journal of Psychopharmacology</i> , 2008, 22, 567-571.	2.0	30
154	Striatal dopamine and homovanillic acid in Huntington's Disease. <i>Journal of Neural Transmission</i> , 1986, 65, 151-155.	1.4	29
155	Deficits of NMDA receptors and glutamate uptake sites in the frontal cortex in AIDS. <i>NeuroReport</i> , 1999, 10, 3513-3515.	0.6	29
156	Reduced n-acetylaspartate in the temporal cortex of rats reared in isolation. <i>Biological Psychiatry</i> , 2004, 56, 296-299.	0.7	29
157	The Determination and Distribution of 2-Phenylethylamine in Sheep Brain. <i>Journal of Neurochemistry</i> , 1980, 34, 1123-1125.	2.1	28
158	Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus. <i>Journal of Psychopharmacology</i> , 2006, 20, 577-579.	2.0	28
159	Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine. <i>Journal of Psychopharmacology</i> , 2016, 30, 1141-1144.	2.0	28
160	The Pharmacogenetics of Symptom Response to Antipsychotic Drugs. <i>Psychiatry Investigation</i> , 2012, 9, 1.	0.7	28
161	THIORIDAZINE IS NOT SPECIFIC FOR LIMBIC DOPAMINE RECEPTORS. <i>Lancet, The</i> , 1982, 320, 499-500.	6.3	27
162	Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. <i>Neuropharmacology</i> , 1988, 27, 717-719.	2.0	27

#	ARTICLE	IF	CITATIONS
163	[3H]Ditolyguanidine binding to human brain $\alpha$ sites is diminished after haloperidol treatment. <i>European Journal of Pharmacology</i> , 1991, 194, 235-236.	1.7	27
164	BDNF (Val66Met) genetic polymorphism is associated with vulnerability for methamphetamine dependence. <i>Pharmacogenomics</i> , 2015, 16, 1541-1545.	0.6	27
165	Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 1994, 89, 36-40.	2.2	26
166	Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	26
167	Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations. <i>JAMA - Journal of the American Medical Association</i> , 1985, 254, 3067-9.	3.8	26
168	Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls. <i>Archiv Fur Psychiatrie Und Nervenkrankheiten</i> , 1982, 232, 463-471.	0.6	25
169	ALZHEIMER-LIKE BRAIN MONOAMINE DEFICITS IN ADULTS WITH DOWN'S SYNDROME. <i>Lancet, The</i> , 1985, 326, 1368-1369.	6.3	25
170	Actions of antipsychotic drugs on pancreatic $\beta$ -cell function: contrasting effects of clozapine and haloperidol. <i>Journal of Psychopharmacology</i> , 2005, 19, 597-601.	2.0	24
171	The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1421-1425.	1.0	24
172	Pocket Handbook of Psychiatric Drug Treatment, 2nd ed.. <i>American Journal of Psychiatry</i> , 1998, 155, 1621-1621.	4.0	24
173	New Approaches to the Drug Treatment of Schizophrenia. <i>Advances in Pharmacology</i> , 1995, 32, 461-503.	1.2	23
174	Agonist-stimulated GTP $\gamma$ [35S] binding to 5-HT1A receptors in human post-mortem brain. <i>European Journal of Pharmacology</i> , 1999, 386, 313-315.	1.7	23
175	TPH-2 Polymorphisms Interact with Early Life Stress to Influence Response to Treatment with Antidepressant Drugs. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw070.	1.0	23
176	Hippocampal benzodiazepine receptors in schizophrenia. <i>Journal of Neural Transmission</i> , 1993, 93, 151-155.	1.4	22
177	Adolescent escitalopram administration modifies neurochemical alterations in the hippocampus of maternally separated rats. <i>European Neuropsychopharmacology</i> , 2010, 20, 875-883.	0.3	22
178	Subchronic administration of phencyclidine produces hypermethylation in the parvalbumin gene promoter in rat brain. <i>Epigenomics</i> , 2016, 8, 1179-1183.	1.0	22
179	Early-life stress effects on BDNF DNA methylation in first-episode psychosis and in rats reared in isolation. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 108, 110188.	2.5	22
180	Human cytomegalovirus DNA in the temporal cortex of a schizophrenic patient. <i>European Archives of Psychiatry and Neurological Sciences</i> , 1988, 238, 110-113.	0.9	22

#	ARTICLE	IF	CITATIONS
181	Plasma homovanillic acid in untreated schizophrenia " relationship with symptomatology and sex. <i>Journal of Psychiatric Research</i> , 2001, 35, 23-28.	1.5	21
182	Subcellular Pathology of Human Neurodegenerative Disorders: Alzheimer's Type Dementia and Huntington's Disease. <i>Journal of Neurochemistry</i> , 1986, 47, 882-889.	2.1	21
183	Preliminary studies of human cortical 5-HT <sub>2</sub> receptors and their involvement in schizophrenia and neuroleptic drug action. <i>Journal of Neural Transmission Supplementum</i> , 1983, 18, 273-7.	0.5	21
184	The urinary excretion of 2-phenylethylamine in phenylketonuria. <i>Clinica Chimica Acta</i> , 1978, 83, 33-39.	0.5	20
185	2-Phenylethylamine and Amphetamine in Human Brain: Effects of L-Deprenyl in Parkinson's Disease. <i>Biochemical Society Transactions</i> , 1979, 7, 143-145.	1.6	20
186	Search for Cytomegalovirus in Postmortem Brain Tissue from Patients with Huntington's Chorea and other Psychiatric Disease by Molecular Hybridization Using Cloned DNA. <i>Journal of Neuropathology and Experimental Neurology</i> , 1985, 44, 176-184.	0.9	20
187	Genetic variation of GRIN1 confers vulnerability to methamphetamine-dependent psychosis in a Thai population. <i>Neuroscience Letters</i> , 2013, 551, 58-61.	1.0	20
188	Development and evaluation of a dimensionless mechanistic pan coating model for the prediction of coated tablet appearance. <i>International Journal of Pharmaceutics</i> , 2017, 528, 180-201.	2.6	20
189	Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 1-14.	1.2	20
190	Phenylethylamine " a role in mental illness?. <i>Trends in Neurosciences</i> , 1979, 2, 265-268.	4.2	19
191	TRACE AMINE DEFICIT IN DEPRESSIVE ILLNESS: THE PHENYLALANINE CONNEXION. <i>Acta Psychiatrica Scandinavica</i> , 1980, 61, 29-39.	2.2	19
192	Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the adrenal glands as well as the brain in the marmoset. <i>Neuroscience Letters</i> , 1985, 58, 123-126.	1.0	19
193	Decreased brown adipose tissue thermogenic activity following a reduction in brain serotonin by intraventricular p-chlorophenylalanine. <i>Bioscience Reports</i> , 1987, 7, 121-127.	1.1	19
194	Glutamate stimulates dopamine release from cortical and limbic rat brain in vitro. <i>European Journal of Pharmacology</i> , 1993, 242, 183-187.	1.7	19
195	Association of a functional <i>FAAH</i> polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population. <i>Pharmacogenomics</i> , 2013, 14, 505-514.	0.6	19
196	Methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 485-490.	1.0	19
197	Genetic association of LMAN2L gene in schizophrenia and bipolar disorder and its interaction with ANK3 gene polymorphism. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 54, 157-162.	2.5	19
198	Blood oxygen level-dependent signals via fMRI in the mood-regulating circuit using two animal models of depression are reversed by chronic escitalopram treatment. <i>Behavioural Brain Research</i> , 2016, 311, 210-218.	1.2	19

#	ARTICLE	IF	CITATIONS
199	Post-mortem neurochemistry of schizophrenia. <i>Psychological Medicine</i> , 1988, 18, 793-797.	2.7	18
200	Antipsychotic drug affinities at $\alpha$ 2-adrenoceptor subtypes in post-mortem human brain. <i>Journal of Psychopharmacology</i> , 1998, 12, 151-154.	2.0	18
201	Analysis of sociability and preference for social novelty in the acute and subchronic phencyclidine rat. <i>Journal of Psychopharmacology</i> , 2014, 28, 955-963.	2.0	18
202	Neuropharmacology: Pathophysiology of schizophrenia " causal role for dopamine or noradrenaline?. <i>Nature</i> , 1983, 305, 577-577.	13.7	17
203	Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a post mortem study. <i>Journal of Neural Transmission</i> , 1992, 87, 225-230.	1.4	17
204	Free radical damage in Down's syndrome brain. <i>Biochemical Society Transactions</i> , 1993, 21, 221S-221S.	1.6	17
205	Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse. <i>Human Molecular Genetics</i> , 2010, 19, 3402-3412.	1.4	17
206	A method for the estimation of 2-phenylethylamine in human urine by gas chromatography. <i>Clinica Chimica Acta</i> , 1976, 70, 213-217.	0.5	16
207	Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinson's disease.. <i>British Journal of Clinical Pharmacology</i> , 1980, 9, 98-99.	1.1	16
208	Consensus on minimal criteria of clinical and neuropathological diagnosis of schizophrenia and affective disorders for post mortem research. <i>Journal of Neural Transmission</i> , 1995, 102, 255-264.	1.4	16
209	An in vitro model of inflammatory neurodegeneration and its neuroprotection. <i>Neuroscience Letters</i> , 2005, 388, 39-44.	1.0	16
210	A correlative study on hippocampal cation shifts and amino acids and clinico-pathological data in Alzheimer's disease. <i>Neurobiology of Aging</i> , 1987, 8, 487-494.	1.5	15
211	Neurotransmitter Systems in Schizophrenia. <i>International Review of Neurobiology</i> , 1995, 38, 305-339.	0.9	15
212	An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease. <i>Journal of Neural Transmission</i> , 1995, 102, 67-73.	1.4	15
213	Pharmacogenetics of schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1429-1440.	0.9	15
214	Single drop behaviour in a high shear granulator. <i>Powder Technology</i> , 2009, 189, 357-364.	2.1	15
215	Effect of Methamphetamine Exposure on Expression of Calcium Binding Proteins in Rat Frontal Cortex and Hippocampus. <i>Neurotoxicity Research</i> , 2016, 30, 427-433.	1.3	15
216	Does DNA methylation influence the effects of psychiatric drugs?. <i>Epigenomics</i> , 2016, 8, 309-312.	1.0	15

#	ARTICLE	IF	CITATIONS
217	Brain serotonin receptors in Huntington's disease. <i>Neurochemistry International</i> , 1986, 9, 431-435.	1.9	14
218	Raised cerebrospinal fluid phenylacetic acid concentration: preliminary support for the phenylethylamine hypothesis of schizophrenia?. <i>Communications in Psychopharmacology</i> , 1978, 2, 199-202.	0.3	14
219	Status of the dopaminergic system in post-mortem brain in schizophrenia. <i>Psychopharmacology Bulletin</i> , 1988, 24, 345-7.	0.0	14
220	Maintenance of cortical somatostatin and monoamine levels in the rat does not require intact cholinergic innervation. <i>Brain Research</i> , 1987, 406, 326-329.	1.1	13
221	Reduced d-[3H]aspartate binding in Down's syndrome brains. <i>Brain Research</i> , 1989, 484, 273-278.	1.1	13
222	Determination of a wide range of urinary amine metabolites using a simple high-performance liquid chromatographic technique. <i>Biomedical Applications</i> , 1981, 225, 179-184.	1.7	12
223	Banbury Report 15, Biological Aspects of Alzheimer's Disease. <i>Trends in Pharmacological Sciences</i> , 1984, 5, 246.	4.0	12
224	[3H]Nipecotic Acid Binding to ?-Aminobutyric Acid Uptake Sites in Postmortem Human Brain. <i>Journal of Neurochemistry</i> , 1990, 55, 165-168.	2.1	12
225	Pallidal GABA and chorea in Huntington's disease. <i>Journal of Neural Transmission</i> , 1990, 81, 241-246.	1.4	12
226	Deficit of [3H]L-689,560 binding to the glycine site of the glutamate/NMDA receptor in the brain in Huntington's disease. <i>Journal of the Neurological Sciences</i> , 1994, 125, 46-49.	0.3	12
227	Glutamate in Huntington's disease. <i>Lancet, The</i> , 1994, 344, 189-190.	6.3	12
228	The effect of chronic antipsychotic treatment on sexual behaviour, hormones and organ size in the male rat. <i>Journal of Psychopharmacology</i> , 2007, 21, 428-434.	2.0	12
229	Acute tryptophan depletion does not alter central or plasma brain-derived neurotrophic factor in the rat. <i>European Neuropsychopharmacology</i> , 2008, 18, 317-322.	0.3	12
230	Increased DNA methylation in the parvalbumin gene promoter is associated with methamphetamine dependence. <i>Pharmacogenomics</i> , 2017, 18, 1317-1322.	0.6	12
231	Parvalbumin Promoter Methylation Altered in Major Depressive Disorder. <i>International Journal of Medical Sciences</i> , 2019, 16, 1207-1214.	1.1	12
232	Decreased Proline Endopeptidase Activity in the Basal Ganglia in Huntington's Disease. <i>Journal of Neurochemistry</i> , 1984, 43, 878-880.	2.1	11
233	The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks. <i>Journal of Psychopharmacology</i> , 2010, 24, 1-8.	2.0	11
234	The Dose-Dependent Effect of Chronic Administration of Haloperidol, Risperidone, and Quetiapine on Sexual Behavior in the Male Rat. <i>Journal of Sexual Medicine</i> , 2011, 8, 3345-3353.	0.3	11

#	ARTICLE	IF	CITATIONS
235	Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone. <i>Human Psychopharmacology</i> , 2014, 29, 38-45.	0.7	11
236	Lower uric acid is associated with poor short-term outcome and a higher frequency of posterior arterial involvement in ischemic stroke. <i>Neurological Sciences</i> , 2018, 39, 1117-1119.	0.9	11
237	Genetic variation of GRIA3 gene is associated with vulnerability to methamphetamine dependence and its associated psychosis. <i>Journal of Psychopharmacology</i> , 2018, 32, 309-315.	2.0	11
238	Changes of BDNF exon IV DNA methylation are associated with methamphetamine dependence. <i>Epigenomics</i> , 2021, 13, 953-965.	1.0	11
239	Chronic haloperidol or clozapine treatment does not alter parvalbumin immunoreactivity in the rat frontal cortex or hippocampus. <i>Neuroscience Letters</i> , 2004, 373, 57-60.	1.0	10
240	Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration. <i>BMC Medical Genetics</i> , 2012, 13, 91.	2.1	10
241	Dopamine Metabolism in Human Brain: Effects of Monoamine Oxidase Inhibition in vitro by (â€”)Deprenyl and (+) and (â€”)Tranlylcypromine. , 1980, , 173-178.		10
242	Dopamine D4 receptors in schizophrenia?. <i>Journal of Neurochemistry</i> , 1996, 66, 881-3.	2.1	10
243	Gas chromatographic detection of N-methyl-2-phenylethylamine: a new component of human urine. <i>Biomedical Applications</i> , 1978, 145, 137-140.	1.7	9
244	The effects of lisuride and some other dopaminergic agonists on receptor binding in human brain. <i>Journal of Neural Transmission</i> , 1981, 51, 107-111.	1.4	9
245	ALUMINIUM AND ALZHEIMER'S DISEASE. <i>Lancet, The</i> , 1989, 333, 267-269.	6.3	9
246	Tissue banking and EURAGE. <i>Journal of the Neurological Sciences</i> , 1989, 93, 341-343.	0.3	9
247	Dopamine receptors and schizophrenia. <i>Biochemical Society Transactions</i> , 1996, 24, 202-205.	1.6	9
248	Weight gain, antipsychotic drug treatment and pharmacogenomics. <i>Pharmacogenomics</i> , 2002, 3, 567-570.	0.6	9
249	Sub-chronic phencyclidine administration increases brain-derived neurotrophic factor in the RAT hippocampus. <i>Schizophrenia Research</i> , 2007, 94, 371-372.	1.1	9
250	The effect of chronic antipsychotic drug administration on nitric oxide synthase activity and gene expression in rat penile tissues. <i>European Neuropsychopharmacology</i> , 2010, 20, 211-217.	0.3	9
251	Polymorphisms of serotonin neurotransmission and their effects on antipsychotic drug action. <i>Pharmacogenomics</i> , 2014, 15, 1599-1609.	0.6	9
252	Circulating microRNA changes in patients with impaired glucose regulation. <i>Adipocyte</i> , 2020, 9, 443-453.	1.3	9



#	ARTICLE	IF	CITATIONS
253	Postmortem Neurochemical Studies in Schizophrenia. , 1987, , 236-240.		9
254	Parkinson's disease putamen: Normal concentration of synaptic membrane marker antigens. Journal of Neural Transmission, 1982, 54, 171-179.	1.4	8
255	LITHIUM PROPHYLAXIS INHIBITS CHOLINE TRANSPORT IN POST-MORTEM BRAIN. Lancet, The, 1986, 328, 458.	6.3	8
256	Neocortical neurotransmitter markers in Huntington's disease. Journal of Neural Transmission, 1994, 98, 197-207.	1.4	8
257	The Effect of Chronic Antipsychotic Drug on Hypothalamic Expression of Neural Nitric Oxide Synthase and Dopamine D2 Receptor in the Male Rat. PLoS ONE, 2012, 7, e33247.	1.1	8
258	Uric Acid and High-Density Lipoprotein Cholesterol Are Differently Associated with Alzheimer's Disease and Vascular Dementia. Journal of Alzheimer's Disease, 2020, 73, 1125-1131.	1.2	8
259	Epigenetic-mediated <i>N</i> -methyl-D-aspartate receptor changes in the brain of isolated reared rats. Epigenomics, 2020, 12, 1983-1997.	1.0	8
260	Metabolic syndrome and schizophrenia. British Journal of Psychiatry, 2006, 188, 86-86.	1.7	8
261	The effect of urinary pH and flow rate on monoamine output. Clinica Chimica Acta, 1978, 84, 225-231.	0.5	7
262	Tranlycypromine Isomers in the Treatment of Parkinson's Disease. International Pharmacopsychiatry, 1981, 16, 30-33.	0.4	7
263	SEROTONIN RECEPTORS IN SUICIDE VICTIMS. Lancet, The, 1983, 322, 977.	6.3	7
264	5-Hydroxytryptamine deficits in the caudate nucleus in AIDS. Aids, 1996, 10, 1303-1304.	1.0	7
265	The neurochemistry of schizophrenia. Psychiatry (Abingdon, England), 2008, 7, 425-429.	0.2	7
266	Association of polymorphisms in <i>GAD1</i> and <i>GAD2</i> genes with methamphetamine dependence. Pharmacogenomics, 2017, 18, 17-22.	0.6	7
267	Neurochemical-clinical correlates in Huntington's disease--applications of brain banking techniques. Journal of Neural Transmission Supplementum, 1993, 39, 207-14.	0.5	7
268	The pharmacology of Parkinson's disease: l-dopa and beyond. Trends in Pharmacological Sciences, 1984, 5, 25-27.	4.0	6
269	D-aspartate binding to the glutamate uptake site in human brain tissue ? effects of leucotomy. Journal of Neural Transmission, 1993, 94, 147-152.	1.4	6
270	5-HT receptors, genes and antipsychotic mechanisms. Journal of Psychopharmacology, 1997, 11, 26-27.	2.0	6



#	ARTICLE	IF	CITATIONS
271	Schizophrenia, antipsychotics and metabolic disease. <i>Journal of Psychopharmacology</i> , 2007, 21, 355-356.	2.0	6
272	Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 314-317.	0.9	6
273	Association study of the functional Catechol-O-Methyltransferase (COMT) Val <sup>158</sup> /Met polymorphism on executive cognitive function in a Thai sample. <i>International Journal of Medical Sciences</i> , 2019, 16, 1461-1465.	1.1	6
274	High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?. <i>Journal of Psychopharmacology</i> , 2021, 35, 1030-1036.	2.0	6
275	The neurochemical pathology of schizophrenia: post-mortem studies from dopamine to parvalbumin. <i>Journal of Neural Transmission</i> , 2022, 129, 643-647.	1.4	6
276	Antipsychotic drug use in neurodegenerative disease in the elderly: problems and potential from a pharmacological perspective. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 543-548.	0.9	5
277	Histamine and antipsychotic drug-induced weight gain. <i>Journal of Psychopharmacology</i> , 2012, 26, 1608-1609.	2.0	5
278	The Pharmacogenetics of Antipsychotic Treatment. <i>Handbook of Experimental Pharmacology</i> , 2012, , 213-239.	0.9	5
279	The relationship of childhood trauma and DNA methylation of NMDA receptor genes in first-episode schizophrenia. <i>Epigenomics</i> , 2021, 13, 927-937.	1.0	5
280	Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. <i>Journal of Psychopharmacology</i> , 0, , .	2.0	5
281	HPLC analysis of somatostatin related peptides in putamen of Huntington's Disease patients. <i>Journal of Neural Transmission</i> , 1987, 69, 153-160.	1.4	4
282	Neurochemical abnormalities in huntington's disease: Neurotoxic mechanisms and neurotransmitter changes. <i>Journal of the Neurological Sciences</i> , 1992, 113, 230-231.	0.3	4
283	Receptor mechanisms of antipsychotic drug atypicality. <i>European Psychiatry</i> , 1998, 13, 5s-8s.	0.1	4
284	The new antipsychotics - some pharmacological aspects of their problems and potential. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 181-185.	0.9	4
285	Does elevated peripheral benzodiazepine receptor gene expression relate to cognitive deficits in methamphetamine dependence?. <i>Human Psychopharmacology</i> , 2016, 31, 243-246.	0.7	4
286	Schizophrenia, Depressive Symptoms, and Antipsychotic Drug Treatment. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 253-255.	1.0	4
287	Brain Biochemistry in Schizophrenia: An Assessment. , 1985, , 35-43.		4
288	Subchronic PCP effects on DNA methylation and protein expression of NMDA receptor subunit genes in the prefrontal cortex and hippocampus of female rats. <i>Journal of Psychopharmacology</i> , 2022, 36, 238-244.	2.0	4

#	ARTICLE	IF	CITATIONS
289	Tranlycypromine Isomers in Parkinson's Disease. <i>Modern Problems of Pharmacopsychiatry</i> , 1983, 19, 154-161.	2.5	3
290	Differential regulation of cardiac $\alpha_1$ - and $\alpha_2$ -adrenoceptors by the sympathetic nervous system. <i>Autonomic and Autacoid Pharmacology</i> , 1994, 14, 29-36.	0.7	3
291	Transgenic models and subcellular pathology "do they tell us what goes wrong in Huntington's disease?". <i>Molecular Psychiatry</i> , 1998, 3, 192-195.	4.1	3
292	Neuromyelitis optica spectrum disorder in three generations of a Chinese family. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 32, 94-96.	0.9	3
293	Agricultural work and reduced circulating uric acid are both associated with initial hospital admission for Parkinson's disease. <i>Journal of Neural Transmission</i> , 2020, 127, 779-783.	1.4	3
294	Early life trauma, DNA methylation and mental illness. <i>Epigenomics</i> , 2021, 13, 825-827.	1.0	3
295	Dopamine receptors and schizophrenia. <i>Biochemical Society Transactions</i> , 1996, 24, 202-5.	1.6	3
296	Recombinant DNA studies on stored necropsy brain samples from patients with Huntington's chorea.. <i>Journal of Clinical Pathology</i> , 1985, 38, 1093-1095.	1.0	2
297	Regional distribution of a novel peptide (P7 of 1B236) immunoreactivity in the human central nervous system. <i>Neuroscience Letters</i> , 1986, 67, 58-62.	1.0	2
298	Neuropathology of Huntington's disease. <i>Trends in Neurosciences</i> , 1987, 10, 404.	4.2	2
299	Schizophrenia - advances in drug therapy. <i>Expert Opinion on Investigational Drugs</i> , 1997, 6, 857-866.	1.9	2
300	Developments in antipsychotic drugs "an update. <i>Expert Opinion on Investigational Drugs</i> , 1998, 7, 257-260.	1.9	2
301	The neurochemistry of schizophrenia. <i>Psychiatry (Abingdon, England)</i> , 2005, 4, 21-25.	0.2	2
302	Functional Pharmacogenetics of Serotonin Receptors in Psychiatric Drug Action. <i>Handbook of Behavioral Neuroscience</i> , 2010, , 791-806.	0.7	2
303	An association between genotypic variations and protein expression of the glial glutamate transporter 2 in the human nucleus accumbens. <i>Neuroscience Letters</i> , 2012, 523, 108-110.	1.0	2
304	Concurrent Risperidone Administration Attenuates the Development of Locomotor Sensitization Following Sub-Chronic Phencyclidine in Rats. <i>Pharmacopsychiatry</i> , 2016, 49, 62-65.	1.7	2
305	Interaction Between Variations in Dopamine D2 and Serotonin 2A Receptor is Associated with Short-Term Response to Antipsychotics in Schizophrenia. <i>Neuroscience Bulletin</i> , 2019, 35, 1102-1105.	1.5	2
306	CACNA1C methylation: association with cortisol, perceived stress, rs1006737 and childhood trauma in males. <i>Epigenomics</i> , 2020, 12, 1739-1749.	1.0	2

#	ARTICLE	IF	CITATIONS
307	Functional pharmacogenetics of serotonin receptors in psychiatric drug action. Handbook of Behavioral Neuroscience, 2020, 31, 941-957.	0.7	2
308	The Etiology of Metabolic Disturbances in Schizophrenia: Drugs, Genes, and Environment. International Journal of Neuropsychopharmacology, 2021, 24, 854-855.	1.0	2
309	Amygdala Dopamine Asymmetry in Schizophrenia: Neurochemical Evidence for a Left Temporal Lobe Dysfunction. , 1986, , 285-291.		2
310	Receptors, Neuroleptics and Dopamine Concentrations in Schizophrenia – Postmortem Studies of Human Brain Tissue. , 1985, , 29-34.		2
311	Muscarinic M1 receptors in schizophrenia. Molecular Psychiatry, 1996, 1, 364-6.	4.1	2
312	DOPAMINE RECEPTORS IN POST-MORTEM SCHIZOPHRENIC BRAINS. Lancet, The, 1981, 317, 1261.	6.3	1
313	Assessment of MAO Inhibitors Using Postmortem Human Brain Tissue: Biochemical and Therapeutic Implications. Modern Problems of Pharmacopsychiatry, 1983, 19, 255-259.	2.5	1
314	NEUROCHEMICAL ASYMMETRY OF THE LIMBIC SYSTEM IN SCHIZOPHRENIA. Clinical Neuropharmacology, 1984, 7, S496.	0.2	1
315	Ascending Systems in Alzheimer's Disease. Interdisciplinary Topics in Gerontology and Geriatrics, 1985, 19, 198-212.	2.6	1
316	Neurochemical Studies in Human Postmortem Brain Tissue. , 1985, , 477-496.		1
317	Alzheimer-like cortical amino-acid changes in elderly Down's syndrome. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1989, 1, 118-118.	1.2	1
318	No deficit of pallidal D2 dopamine receptors in Huntington's disease. Journal of the Neurological Sciences, 1990, 100, 238.	0.3	1
319	The ratio of plasma phenylalanine to other large neutral amino acids is not a risk factor for tardive dyskinesia. Journal of Psychopharmacology, 1992, 6, 278-280.	2.0	1
320	Studies on brain monoamine oxidase: a laboratory investigation in neurochemistry for first-year undergraduates. Biochemical Education, 1992, 20, 55-56.	0.1	1
321	An improved model for examining delayed excitotoxic neurodegeneration in isolated chick retina. Neuroscience Letters, 1996, 219, 65-67.	1.0	1
322	Dopamine receptors, antipsychotic action and schizophrenia. Journal of Psychopharmacology, 1999, 13, 202-203.	2.0	1
323	Association of brain-derived neurotrophic factor valine to methionine polymorphism with sexual dysfunction following selective serotonin reuptake inhibitor treatment in female patients with major depressive disorder. Asia-Pacific Psychiatry, 2016, 8, 260-268.	1.2	1
324	S14. DNA METHYLATION CHANGES IN GABAERGIC AND GLUTAMATERGIC MARKERS IN EARLY SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S329-S329.	2.3	1

#	ARTICLE	IF	CITATIONS
325	Phenylethylamine and Schizophrenia – Clinical and Pharmacological Results. , 1984, , 515-523.		1
326	Association of SLC1A2 and SLC17A7 polymorphisms with major depressive disorder in a Thai population. Asian Biomedicine, 2019, 12, 131-138.	0.2	1
327	Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia. Acta Pharmacologica Sinica, 2001, 22, 76-80.	2.8	1
328	Early and late onset types of Alzheimer's disease. BMJ: British Medical Journal, 1984, 288, 1612-1612.	2.4	0
329	Noradrenaline and schizophrenia. Trends in Pharmacological Sciences, 1984, 5, 138.	4.0	0
330	GLUTAMATE DEHYDROGENASE ACTIVITY IN AMYOTROPHIC LATERAL SCLEROSIS. Lancet, The, 1988, 332, 914.	6.3	0
331	Neurotransmitter receptors, genes and schizophrenia. European Neuropsychopharmacology, 1996, 6, S4-29-S4-30.	0.3	0
332	S.17.03 Antipsychotic drugs and neurotransmitter receptor regulation. European Neuropsychopharmacology, 1997, 7, S110-S111.	0.3	0
333	Neurochemistry of Human Postmortem Brain. , 1999, , 319-346.		0
334	What's new in – The neurochemistry of schizophrenia. Medicine, 2004, 32, 1-4.	0.2	0
335	PHARMACOGENETICS OF THE METABOLIC CONSEQUENCES OF ANTIPSYCHOTIC DRUGS. Schizophrenia Research, 2008, 102, 240.	1.1	0
336	MALE SEXUAL DYSFUNCTION IN SCHIZOPHRENIA: RELATIONSHIP WITH DRUG TREATMENT, PROLACTIN AND DRD2 GENOTYPE. Schizophrenia Research, 2010, 117, 506.	1.1	0
337	Special issue on Pharmacogenetics. Journal of Psychopharmacology, 2012, 26, 333-333.	2.0	0
338	Poster #M168 DNA METHYLATION OF THE 5-HT1A RECEPTOR GENE PROMOTER IS ASSOCIATED WITH NEGATIVE SYMPTOM RESPONSE TO ANTIPSYCHOTIC DRUG TREATMENT. Schizophrenia Research, 2014, 153, S251-S252.	1.1	0
339	Editorial: Pharmacogenomics and psychiatric disease. Neuroscience Letters, 2020, 726, 134602.	1.0	0
340	S8. GRIN1 PROMOTER METHYLATION CHANGES IN BLOOD OF EARLY-ONSET PSYCHOTIC PATIENTS AND UNAFFECTED SIBLINGS WITH CHILDHOOD TRAUMA. Schizophrenia Bulletin, 2020, 46, S32-S33.	2.3	0
341	Antipsychotics, Weight Gain and Metabolic Risk. , 2020, , 619-619.		0
342	M9. RATS REARED IN SOCIAL ISOLATION INDUCES EPIGENETIC MODIFICATIONS IN THE NMDA RECEPTOR SUBUNITS. Schizophrenia Bulletin, 2020, 46, S136-S136.	2.3	0

#	ARTICLE	IF	CITATIONS
343	Pharmacological Management of Neurological and Psychiatric Disorders. American Journal of Psychiatry, 2001, 158, 1539-1540.	4.0	0
344	Dopamine Function and Neuroleptics in Schizophrenia – Post-Mortem Studies of Human Brain Tissue. , 1985, , 209-213.		0
345	Dopamine D2 -Receptors in Post-mortem Human Brains from Schizophrenic Patients. , 1990, , 507-513.		0
346	Alzheimer-like changes of cortical amino acid transmitters in elderly Downâ€™s syndrome. Key Topics in Brain Research, 1990, , 283-288.	0.2	0
347	Cholinergic Basis for Alzheimer Therapy. American Journal of Psychiatry, 1993, 150, 1265-1265.	4.0	0
348	Brain derived neurotrophic factor (BDNF) methylation in patients with impaired glucose regulation: implications progression to type 2 diabetes mellitus (T2DM). Endocrine Abstracts, 0, , .	0.0	0
349	CACNA1C genotype does influence CACNA1C methylation and the association with cortisol release/potential mental health resilience. Endocrine Abstracts, 0, , .	0.0	0
350	M210. GRIN2B METHYLATION IS RELATED TO PANSS EXCITED COMPONENT (PANSS-EC) IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S216-S216.	2.3	0
351	Tranlycypromine isomers and Parkinson's disease: new aspects of an old drug. Journal of the Royal Society of Medicine, 1981, 74, 649-52.	1.1	0
352	Dopamine Receptors: Receptor Biochemistry and Methodology, vol. 8. American Journal of Psychiatry, 1989, 146, 672-673.	4.0	0